Litigation Details for Par Pharmaceutical, Inc. v. Hospira, Inc. (D. Del. 2017)
✉ Email this page to a colleague
Par Pharmaceutical, Inc. v. Hospira, Inc. (D. Del. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-07-13 |
| Court | District Court, D. Delaware | Date Terminated | 2019-11-14 |
| Cause | 35:271 Patent Infringement | Assigned To | Joseph F. Bataillon |
| Jury Demand | None | Referred To | Sherry R. Fallon |
| Patents | 9,119,876; 9,295,657 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Par Pharmaceutical, Inc. v. Hospira, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Par Pharmaceutical, Inc. v. Hospira, Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2017-07-13 | 1 | Complaint | U.S. Patent No. 9,119,876 (“the ’876 patent”) and U.S. Patent No. 9,295,657 (“the ’657 patent”) (collectively…collectively, the “Patents-in-Suit”) pursuant to the Patent Laws of the United States, 35 U.S.C. § 1, … THE PATENTS-IN-SUIT 9. The ’876 patent, titled “Epinephrine Formulations… of the ’876 patent is attached hereto as Exhibit A. 11. The ’657 patent, titled “Epinephrine…Par obtained the ’876 and ’657 patents. 21. The ’876 patent covers the technological advance | External link to document |
| 2018-11-15 | 120 | Notice of Service | Amended Invalidity Contentions on U.S. Patent Nos. 9,119,876 and 9,295,657 filed by Hospira, Inc..(Haney… 14 November 2019 1:17-cv-00944 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-06-04 | 189 | Memorandum and Order | expiration of Par’s patents covering Adrenalin®, U.S. Patent Nos. 9,119,876 (“the ’876 patent”) and 9,295,657…,657 (“the ’657 patent”) (together, “the Patents-in-Suit”) (Exs. 1-2). Par contends that Hospira’s ANDA…contention that if a patent describes only a single embodiment, the claims of the patent must be construed…112 of the Patent Act requires that the claims themselves set forth the limits of the patent grant, but… ANDA Product infringes the Patents-in-Suit under 35 U.S.C. § 271(e)(2), and that the manufacture, use | External link to document |
| 2019-06-04 | 190 | Memorandum and Order | expiration of Par’s patents covering Adrenalin®, U.S. Patent Nos. 9,119,876 (“the ’876 patent”) and 9,295,657…9,295,657 (“the ’657 patent”) (together, “the Patents-in- Suit”) (D.I. 1, Exs. 1-2). The patents-in-suit are …letter request for sanctions (D.I. 124). This is a patent infringement case arising under the Hatch-Waxman…the conditions specified by claims 12-19 of the patents-in-suit.” D.I. 54. While the parties were… 14 November 2019 1:17-cv-00944 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
